LAURUSLABS Share Price Performance
₹1,021.40
449.50 (78.60%)
24.3% overvalued intrinsic discount
₹821.93
Fair Value
Price ₹1,021.40
AnalystConsensusTarget ₹821.93
AnalystLowTarget ₹293.00
AnalystHighTarget ₹1,025.00
Fair Value₹821.93
Share Pricen/a
Laurus Labs Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
LAURUSLABS Community Narratives
AN
Fair Value ₹821.93 24.3% overvalued intrinsic discount
LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
Fair Value ₹303.09 237.0% overvalued intrinsic discount
Global Healthcare Regulation Will Squeeze Margins Amid Rising Costs
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value ₹1.03k 0.4% undervalued intrinsic discount
Digital Transformation And Affordable Generics Will Expand Global Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings
Key Takeaways Enthusiasm centers on Laurus Labs' expansion in CDMO and diversified therapies, expecting swift returns from aggressive investment and new high-value segments. Risks include high debt, ongoing capital needs, regulatory obstacles, and global drug price pressures that could disrupt earnings and margin growth.Read more
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
₹821.93
24.3% overvalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
13.46% p.a.
Profit Margin
14.64%
Future PE
46.89x
Price in 2028
₹1.18k
Digital Transformation And Affordable Generics Will Expand Global Markets
Key Takeaways Management's strategy leverages advanced technology and diversified platforms to drive structurally higher margins and accelerate both revenue and product pipeline growth. Investments in digitalization and new verticals position Laurus Labs for rapid market expansion, sustained earnings resilience, and efficient global opportunity capture.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
₹1.03k
0.4% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
15.92% p.a.
Profit Margin
19.22%
Future PE
45.49x
Price in 2028
₹1.47k
Global Healthcare Regulation Will Squeeze Margins Amid Rising Costs
Key Takeaways Regulatory changes and sustainable manufacturing trends are set to elevate costs and compress margins, challenging Laurus Labs' long-term profitability. Shifts in industry focus and pricing pressures, combined with underperforming new divisions and intense competition, threaten growth and core business relevance.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
₹303.09
237.0% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
11.96% p.a.
Profit Margin
12.36%
Future PE
23.22x
Price in 2028
₹433.62
Trending Discussion
Recently Updated Narratives
AN
LAURUSLABS: Future Returns Will Likely Hinge On Managing Execution Risks
Fair Value: ₹821.93 24.3% overvalued intrinsic discount
13 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Global Healthcare Regulation Will Squeeze Margins Amid Rising Costs
Fair Value: ₹303.09 237.0% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Digital Transformation And Affordable Generics Will Expand Global Markets
Fair Value: ₹1.03k 0.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Laurus Labs Limited Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 12.67
- 55.90%
- 10.76%
- 43.6%
About LAURUSLABS
- Founded
- 2005
- Employees
- 6167
- CEO
- WebsiteView website
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
